$DPHARMA (7148.MY)$ announced that its subsidiary Duopharma (M) Sdn Bhd (DMS) has secured a contract worth RM155.28 million to supply insulin products to public healthcare institutions nationwide.
The three-year contract will run from June 3, 2026, to June 2, 2029.
Under the contract, DMS will supply recombinant human insulin 100 IU/ml Penfill/Refill products, covering rapid-acting, intermediate-acting, and premixed insulin formulations, as well as reusable insulin pens.
This means that, for the next three years, the relevant insulin products will be supplied for use across the national government healthcare system.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.Read more
Comment (1)
to post a comment
2